Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes
CA 2397059 A1 · Owner: Kessler, Johan Herman · Inventors: Kessler, Johan Herman; Ossendorp, Ferry; Melief, Cornelis Johannes Maria
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
We systematically investigated proteasome-mediated generation of fourteen different well-defined CTL epitopes. Synthetic peptides (26 residues) containing known CTL-epitopes flanked by their natural amino acids have been used as substrates for the 20S proteasome in vitro. After several time intervals, peptide digests were analyzed by electrospray mass spectrometry to determine the major fragments produced by the proteasome. In 12 out of 14 peptide digests, the correct C-terminal residue of the CTL-epitope was generated by proteasomal cleavage. The N-terminal residue of the epitope was generally not exactly defined by the proteasome. In most cases fragments with , the correct …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 22, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 22, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 22, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.